Tizona Therapeutics
PrivateLast Round
Corporate Funding
Jul 21, 2020
Est. Valuation
$601.2M
Total Funding Raised
$475M
Company Overview
Tizona Therapeutics is a biotechnology company that develops first-in-class immunotherapies to treat cancer and autoimmune diseases by modulating immunosuppressive cell activity in the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tizona Therapeutics Comparables
Compare Tizona Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trishula Therapeutics | 92% | |
| Immune-Onc Therapeutics | 84% | |
| Elpiscience Biopharmaceuticals | 83% |
For institutional investors. Book with your work email.
Tizona Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Jul 21, 2020 | ||||
| Strategic | Jan 3, 2019 | ||||
| Series B | Mar 8, 2016 | ||||
| Series A | Jan 1, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tizona Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series B |
| InterWest Partners | Series B, Series A |
| Lightstone Ventures | Series B |
| MPM BioImpact | Series B, Series A |
| Amgen Ventures | Series B, Series A |
| Abingworth | Series B |
| Canaan Partners | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 3, 2019
$105M round led by AbbVie and Astellas Venture Management.
- Mar 8, 2016
$43M round led by Canaan Partners and Abingworth.
For institutional investors. Book with your work email.
Tizona Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tizona Therapeutics's valuation, stock price, and market status.
Is Tizona Therapeutics a public or private company?
Tizona Therapeutics is a private company.
What is the current stock price of Tizona Therapeutics?
Tizona Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tizona Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tizona Therapeutics worth (valuation)?
Tizona Therapeutics's valuation is estimated at $601.2M based on funding round data.
Can I buy Tizona Therapeutics stock?
Tizona Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tizona Therapeutics's last funding round?
Tizona Therapeutics's most recent funding round was Corporate Funding on July 21, 2020.
Who are the main investors in Tizona Therapeutics?
Key investors in Tizona Therapeutics include Abingworth, Canaan Partners.
Will Tizona Therapeutics IPO soon?
No public IPO plans have been announced for Tizona Therapeutics.
How can I track Tizona Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tizona Therapeutics's shares on secondary markets.